Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel

被引:87
作者
Yanasarn, Nijaporn [1 ]
Sloat, Brian R. [1 ]
Cui, Zhengrong [1 ]
机构
[1] Oregon State Univ, Dept Pharmaceut Sci, Coll Pharm, Corvallis, OR 97331 USA
关键词
Nanoparticles; Emulsions; Cell uptake; Cytotoxicity; Biocompatibility; DRUG-DELIVERY; PHARMACOKINETICS; LIPOSOMES;
D O I
10.1016/j.ijpharm.2009.06.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Docetaxel is a potent anticancer drug. However, there continues to be a need for alternative docetaxel delivery systems to improve its efficacy. We reported the engineering of a novel spherical nanoparticle formulation (similar to 270 nm) from lecithin-in-water emulsions. Docetaxel can be incorporated into the nanoparticles, and the resultant docetaxel-nanoparticles were stable when stored as an aqueous suspension. The release of the docetaxel from the nanoparticles was likely caused by a combination of diffusion and Case II transport. The docetaxel-in-nanoparticles were more effective in killing tumor cells in culture than free docetaxel. Moreover, the docetaxel-nanoparticles did not cause any significant red blood cell lysis or platelet aggregation in vitro, nor did they induce detectable acute liver damage when injected intravenously into mice. Finally, compared to free docetaxel, the intravenously injected docetaxel-nanoparticles increased the accumulation of the docetaxel in a model tumor in mice by 4.5-fold. These lecithin-based nanoparticles have the potential to be a novel biocompatible and efficacious delivery system for docetaxel. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:174 / 180
页数:7
相关论文
共 24 条
[1]   Drug delivery systems: Entering the mainstream [J].
Allen, TM ;
Cullis, PR .
SCIENCE, 2004, 303 (5665) :1818-1822
[2]   Ligand-targeted therapeutics in anticancer therapy [J].
Allen, TM .
NATURE REVIEWS CANCER, 2002, 2 (10) :750-763
[3]   Clinical pharmacokinetics of docetaxel [J].
Clarke, SJ ;
Rivory, LP .
CLINICAL PHARMACOKINETICS, 1999, 36 (02) :99-114
[4]   Lecithin-based cationic nanoparticles as a potential DNA delivery system [J].
Cui, ZR ;
Qiu, F ;
Sloat, BR .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 313 (1-2) :206-213
[5]   Genetic immunization using nanoparticles engineered from microemulsion precursors [J].
Cui, ZR ;
Mumper, RJ .
PHARMACEUTICAL RESEARCH, 2002, 19 (07) :939-946
[6]   Drug delivery and nanoparticles: Applications and hazards [J].
De Jong, Wim H. ;
Borm, Paul J. A. .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2008, 3 (02) :133-149
[7]   The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis [J].
Emerich, Dwaine F. ;
Thanos, Christopher G. .
BIOMOLECULAR ENGINEERING, 2006, 23 (04) :171-184
[8]   Pharmacokinetics of pegylated liposomal doxorubicin - Review of animal and human studies [J].
Gabizon, A ;
Shmeeda, H ;
Barenholz, Y .
CLINICAL PHARMACOKINETICS, 2003, 42 (05) :419-436
[9]   Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles [J].
Hwang, Ho-Young ;
Kim, In-San ;
Kwon, Ick Chan ;
Kim, Yong-Hee .
JOURNAL OF CONTROLLED RELEASE, 2008, 128 (01) :23-31
[10]   Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel [J].
Immordino, ML ;
Brusa, P ;
Arpicco, S ;
Stella, B ;
Dosio, F ;
Cattel, L .
JOURNAL OF CONTROLLED RELEASE, 2003, 91 (03) :417-429